251 related articles for article (PubMed ID: 26810044)
1. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential.
Soyka M
Expert Opin Pharmacother; 2016; 17(4):619-26. PubMed ID: 26810044
[TBL] [Abstract][Full Text] [Related]
2. Nalmefene for the treatment of alcohol dependence: a current update.
Soyka M
Int J Neuropsychopharmacol; 2014 Apr; 17(4):675-84. PubMed ID: 24246244
[TBL] [Abstract][Full Text] [Related]
3. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
Soyka M; Friede M; Schnitker J
Pharmacopsychiatry; 2016 Mar; 49(2):66-75. PubMed ID: 26845589
[TBL] [Abstract][Full Text] [Related]
4. Opioid Receptor Antagonists in the Treatment of Alcoholism.
Serecigni JG
Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological profile and clinical findings of nalmefene (Selincro
Tadori Y
Nihon Yakurigaku Zasshi; 2020; 155(2):113-119. PubMed ID: 32115477
[TBL] [Abstract][Full Text] [Related]
6. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy.
Mann K; Torup L; Sørensen P; Gual A; Swift R; Walker B; van den Brink W
Eur Neuropsychopharmacol; 2016 Dec; 26(12):1941-1949. PubMed ID: 27842940
[TBL] [Abstract][Full Text] [Related]
7. [Alcohol dependence and opioid receptor -Pharmacological profile of nalmefene].
Ohgi Y
Nihon Yakurigaku Zasshi; 2020; 155(3):145-148. PubMed ID: 32378631
[TBL] [Abstract][Full Text] [Related]
8. Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.
Palpacuer C; Laviolle B; Boussageon R; Reymann JM; Bellissant E; Naudet F
PLoS Med; 2015 Dec; 12(12):e1001924. PubMed ID: 26694529
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
[TBL] [Abstract][Full Text] [Related]
10. Nalmefene. Alcohol dependence: no advance.
Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
[TBL] [Abstract][Full Text] [Related]
11. Recent Developments in Pharmacotherapy of Alcoholism.
Soyka M; Lieb M
Pharmacopsychiatry; 2015 Jul; 48(4-5):123-35. PubMed ID: 25761458
[TBL] [Abstract][Full Text] [Related]
12. Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.
Quelch DR; Mick I; McGonigle J; Ramos AC; Flechais RSA; Bolstridge M; Rabiner E; Wall MB; Newbould RD; Steiniger-Brach B; van den Berg F; Boyce M; Østergaard Nilausen D; Breuning Sluth L; Meulien D; von der Goltz C; Nutt D; Lingford-Hughes A
Biol Psychiatry; 2017 Jun; 81(11):941-948. PubMed ID: 28216062
[TBL] [Abstract][Full Text] [Related]
13. Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stevenson M; Pandor A; Stevens JW; Rawdin A; Rice P; Thompson J; Morgan MY
Pharmacoeconomics; 2015 Aug; 33(8):833-47. PubMed ID: 25851485
[TBL] [Abstract][Full Text] [Related]
14. Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.
Barrio P; Ortega L; Guardia J; Roncero C; Yuguero L; Gual A
Clin Drug Investig; 2018 Feb; 38(2):147-155. PubMed ID: 29080208
[TBL] [Abstract][Full Text] [Related]
15. Evaluation in alcohol use disorders - insights from the nalmefene experience.
Naudet F; Palpacuer C; Boussageon R; Laviolle B
BMC Med; 2016 Aug; 14(1):119. PubMed ID: 27534932
[TBL] [Abstract][Full Text] [Related]
16. Opioid modulators for alcohol dependence.
Hillemacher T; Heberlein A; Muschler MA; Bleich S; Frieling H
Expert Opin Investig Drugs; 2011 Aug; 20(8):1073-86. PubMed ID: 21651459
[TBL] [Abstract][Full Text] [Related]
17. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
Gual A; He Y; Torup L; van den Brink W; Mann K;
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1432-42. PubMed ID: 23562264
[TBL] [Abstract][Full Text] [Related]
18. A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence.
Laramée P; Millier A; Rahhali N; Cristeau O; Aballéa S; François C; Chalem Y; Toumi M; Rehm J
Appl Health Econ Health Policy; 2016 Aug; 14(4):493-505. PubMed ID: 27283839
[TBL] [Abstract][Full Text] [Related]
19. Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine.
Yéléhé-Okouma M; Martini H; Lemarié J; Labroca P; Petitpain N; Gibaja V; Paille F; Gillet P
Fundam Clin Pharmacol; 2017 Oct; 31(5):574-579. PubMed ID: 28322465
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
van den Brink W; Strang J; Gual A; Sørensen P; Jensen TJ; Mann K
Expert Opin Drug Saf; 2015 Apr; 14(4):495-504. PubMed ID: 25652768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
